DNA Ginkgo Bioworks Holdings Inc
Price (delayed)
$5.96
Market cap
$345.88M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$10.54
Enterprise value
$223.07M
the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline
Highlights
The EPS rose by 43% year-on-year and by 19% since the previous quarter
The net income has grown by 39% YoY and by 16% from the previous quarter
The revenue has declined by 10% year-on-year but it rose by 4.2% since the previous quarter
The gross profit has declined by 8% year-on-year but it is up by 3.4% since the previous quarter
The debt has soared by 98% year-on-year
The equity is down by 35% year-on-year and by 10% since the previous quarter
Key stats
What are the main financial stats of DNA
Market
Valuations
Earnings
Shares outstanding
58.03M
Market cap
$345.88M
Enterprise value
$223.07M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.48
Price to sales (P/S)
1.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.98
Revenue
$227.04M
Gross profit
$182.5M
Operating income
-$559.76M
Net income
-$547.03M
EBIT
-$547.41M
EBITDA
-$456.3M
Free cash flow
-$381.48M
Per share
Balance sheet
Liquidity
EPS
-$10.54
EPS diluted
-$10.54
Free cash flow per share
-$7.35
Book value per share
$12.46
Revenue per share
$4.38
TBVPS
$25.15
Total assets
$1.38B
Total liabilities
$661.39M
Debt
$438.77M
Equity
$716.06M
Working capital
$495.48M
Debt to equity
0.61
Current ratio
5.62
Quick ratio
5.44
Net debt/EBITDA
0.27
Margins
Efficiency
Dividend
EBITDA margin
-201%
Gross margin
80.4%
Net margin
-240.9%
Operating margin
-246.5%
Return on assets
-36.1%
Return on equity
-65.6%
Return on invested capital
-55.3%
Return on capital employed
-43.1%
Return on sales
-241.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DNA stock price
How has the Ginkgo Bioworks Holdings stock price performed over time
Intraday
5.3%
1 week
-10.38%
1 month
-27.67%
1 year
-85.81%
YTD
-39.31%
QTD
4.56%
Financial performance
How have Ginkgo Bioworks Holdings's revenue and profit performed over time
Revenue
$227.04M
Gross profit
$182.5M
Operating income
-$559.76M
Net income
-$547.03M
Gross margin
80.4%
Net margin
-240.9%
The net income has grown by 39% YoY and by 16% from the previous quarter
DNA's operating income is up by 35% year-on-year and by 12% since the previous quarter
The net margin is up by 32% year-on-year and by 19% since the previous quarter
DNA's operating margin is up by 28% YoY and by 15% from the previous quarter
Growth
What is Ginkgo Bioworks Holdings's growth rate over time
Valuation
What is Ginkgo Bioworks Holdings stock price valuation
P/E
N/A
P/B
0.48
P/S
1.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.98
The EPS rose by 43% year-on-year and by 19% since the previous quarter
The price to book (P/B) is 88% lower than the 5-year quarterly average of 3.7 and 63% lower than the last 4 quarters average of 1.2
The equity is down by 35% year-on-year and by 10% since the previous quarter
The stock's price to sales (P/S) is 95% less than its 5-year quarterly average of 27.5 and 73% less than its last 4 quarters average of 4.8
The revenue has declined by 10% year-on-year but it rose by 4.2% since the previous quarter
Efficiency
How efficient is Ginkgo Bioworks Holdings business performance
The company's return on invested capital rose by 35% YoY and by 25% QoQ
The return on sales rose by 32% year-on-year and by 19% since the previous quarter
The company's return on assets rose by 15% YoY and by 12% QoQ
The ROE has grown by 6% from the previous quarter
Dividends
What is DNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DNA.
Financial health
How did Ginkgo Bioworks Holdings financials performed over time
Ginkgo Bioworks Holdings's total assets is 108% higher than its total liabilities
Ginkgo Bioworks Holdings's total assets has decreased by 17% YoY and by 7% QoQ
DNA's total liabilities is up by 16% YoY but it is down by 3.2% from the previous quarter
The debt is 39% smaller than the equity
The debt has soared by 98% year-on-year
The equity is down by 35% year-on-year and by 10% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.